Related Experiment Video
Updated: Feb 14, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Metabolic reprogramming and immunosenescence: a new sight for glioma therapy
Huali Fan1,2, Shizhuo Yang1,2, Qing Lu1,2
1Department of Pharmacy, West China Tianfu Hospital, Sichuan University, Chengdu, China.
Abstract:
Gliomas, the most prevalent primary tumor of the central nervous system, are characterized by a poor prognosis and a high recurrence rate. The glioma microenvironment is highly immunosuppressive, which poses a major obstacle to effective immunotherapy. Metabolic reprogramming is a hallmark of glioma, driving tumor progression and therapy resistance. Key alterations include the Warburg effect, increased glutamine dependency, enhanced pentose phosphate pathway activity, and dysregulated lipid metabolism. Immunosenescence, the age-dependent decline in immune function that contributes to disease pathogenesis, encompasses immune dysregulation, senescence-associated secretory phenotype (SASP) accumulation, and epigenetic changes, which together drive immune cell dysfunction and foster an immunosuppressive microenvironment. Meantime, senescent immune cells may change the metabolic microenvironment, whereas metabolic reprogramming also influence immune system. Thus, this small essay is on the purpose of demonstrating the significance and function of metabolic reprogramming and immunosenescence in gliomas, providing evidence of promising therapeutic strategies.
Insights
Glioma treatment faces challenges due to the tumor microenvironment. This study explores how metabolic reprogramming and immunosenescence impact glioma progression and therapy resistance, offering potential therapeutic strategies.
Area of Science:
- Neuro-oncology
- Cancer Immunology
- Metabolic Pathways
Background:
- Gliomas are primary central nervous system tumors with poor prognosis and high recurrence.
- The glioma microenvironment is immunosuppressive, hindering effective immunotherapy.
- Metabolic reprogramming and immunosenescence are key hallmarks of glioma progression and therapy resistance.
Purpose of the Study:
- To demonstrate the significance and function of metabolic reprogramming in gliomas.
- To elucidate the role of immunosenescence in glioma pathogenesis.
- To provide evidence for promising therapeutic strategies targeting these mechanisms.
Main Methods:
- Review of current literature on glioma metabolism and immunosenescence.
- Analysis of key metabolic alterations (Warburg effect, glutamine dependency, PPP, lipid metabolism).
- Examination of immunosenescence components (immune dysregulation, SASP, epigenetic changes).
Main Results:
- Metabolic reprogramming drives glioma progression and therapy resistance.
- Immunosenescence contributes to immune cell dysfunction and an immunosuppressive microenvironment.
- Interactions exist between senescent immune cells and the metabolic microenvironment, and vice versa.
Conclusions:
- Metabolic reprogramming and immunosenescence are critical factors in glioma.
- Understanding these processes is vital for developing novel glioma therapies.
- Targeting metabolic and immune pathways holds promise for improving glioma treatment outcomes.
Related Concept Videos
Sight Distance in a Vertical Curve
What is Metabolism?
Gene Therapy
Introduction to Nuclear Reprogramming
Methods of Nuclear Reprogramming
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...

